STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

RCUS ARCUS BIOSCIENCES INCORPORATED StockScouter® Report

4

StockScouter® Score

ARCUS BIOSCIENCES INCORPORATED, a small cap growth company in the healthcare sector, is expected to perform in line with the market over the next six months with average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • One or more less experienced analysts has modestly increased quarterly earnings estimates for RCUS. Positive/Neutral
  • Short-term relative price momentum exhibits moderate strength. Postive/Neutral

 

Concerns

  • The enterprise value-to-sales ratio is much higher than the average for comparably-sized companies in the StockScouter universe. Very Negative
  • Earnings growth in the past year has decelerated moderately compared to earnings growth in the past three years. Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that small cap stocks will be out of favor, growth stocks will be out of favor, and healthcare stocks will be out of favor.

Expected Risk/Return

Progress: 60% done.
Progress: 60% done.
Low
High

Core Model Grades

C
C
F
D

Previous Ratings

5
5
5